Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators.
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.
Get weekly health news
The study compared using intismeran and Keytruda together on melanoma patients against using Keytruda alone. The companies said patients who received the combination lived longer without cancer returning or metastasizing than patients who got Keytruda alone.
The companies did not say how long patients survived without cancer returning or whether patients lived longer overall. They said they plan to present the study results at an upcoming international medical meeting.
Moderna shares rose more than 120 per cent to $140.12 a share. Merck shares rose about 11 per cent.
Remember when the first Covid vaccine killed all the residents at a nursing home? Well, the media removed the articles. Remember when young athletes were dying after the covid shots? AI now believes there is no connection to the vaccine. This is the doctoring of information. Now get in line to preorder this next product, because it will be “totally safe”.
How can Moderna be trusted?
How about some news on Ottawa detective Helen Grus, who was recently sentenced for probing a suspicious increase in infant deaths following the rollout of covid shots?
This is the same stuff, from the same company that killed so many when they forced people to take it, calling it a vaccine for Covid.
It was abandoned before Covid, as being too dangerous, as it attacks other cells than those it is supposed to target.
It should be a crime to call it a vaccine. It is gene modification.
The Liberals gave this large company billions to open a shop in Montreal.
Since it must be customized for each person, it is likely to be heinously expensive. No public system will be able to fund it so only the rich will benefit.